Key facts
- Notable investors include Qiangtang (Dalian) Private Equity Fund Management.
- Status: Privately Held (backing).
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Xingyuande Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Xingyuande Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xingyuande Biotechnology
Developer of immunotherapies intended to activate immune responses against infectious diseases and cancerous conditions. The company offers cutting-edge cell engineering platforms and antibody-based treatments, enabling individuals with complex infections and tumours to receive highly targeted therapeutic interventions.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2020
- Ownership
- Privately Held (backing)
Xingyuande Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xingyuande Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xingyuande Biotechnology in its N-PORT filings yet. We sweep new filings monthly.